NVAX:NASDAQ
Novavax Inc
$12.59
arrow_downward
-0.55%(-0.070) 1D
Oct 13, 9:54:13 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$12.44
High
$12.72
Low
$12.21
Mkt. cap
2.08B
Avg. vol.
7.43M
Volume
652.92K
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$12.44
High
$12.72
Low
$12.21
Mkt. cap
2.08B
Avg. vol.
7.43M
Volume
652.92K
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Zacks
·
22 hours ago
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Benzinga
·
1 day ago
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Simply Wall Street
·
2 days ago
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
Yahoo Finance
·
6 days ago
Novavax, Moderna stocks fall after WHO calls plague risk 'low'
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com